ライフサイエンスコーパス: advanced stage

1 nical features when the disease is at a more advanced stage).

2 ely lethal diseases that often present at an advanced stage.

3 rvival outcomes for patients diagnosed at an advanced stage.

4 ase progressing from the intermediate to the advanced stage.

5 apy and is associated with poor prognosis in advanced stage.

6 agnosed late in pregnancy and detected at an advanced stage.

7 ples change as they evolve from early to the advanced stage.

8 rrhosis, and it presents a poor prognosis in advanced stage.

9 aucoma but underestimates damage in moderate~advanced stages.

10 st skin cancer, remains largely incurable at advanced stages.

11 s with low rates of response to treatment at advanced stages.

12 sensitive progression detector from early to advanced stages.

13 early stages from the referable intermediate/advanced stages.

14 der that requires corneal transplantation in advanced stages.

15 ereby both gained significantly in number in advanced stages.

16 e the genomic profiling of HCC from early to advanced stages.

17 Ninety-three patients had advanced stage (50 locally advanced and 43 metastatic) a

18 93.3%; intermediate stages, 72.1% and 96.2%; advanced stages, 69.8% and 87.4%), respectively.

19 I patients, VRE BSI patients were older, had advanced-stage acute leukemia, and received umbilical co

20 mor diameter, para-aortic nodal involvement, advanced stage, ADC90 and ADC95, nADC75, nADC90, and nAD

21 V-infected population, and the propensity to advanced stage, aggressive presentation, and extranodal

22 ority trial, we enrolled people with HIV and advanced stage AIDS-associated Kaposi sarcoma attending

23 In advanced stages, AIG might progress to neuroendocrine tu

24 re its appearance in older male individuals, advanced stage and bilateral manifestation at the time o

25 development, as it is generally detected at advanced stage and is in the need for early diagnosis te

26 lial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecolo

27 Additionally, within PDACs of advanced stage and negative surgical margins, K17 at bot

28 e of diagnosis, the disease is usually at an advanced stage and only a minority is eligible for surgi

29 Advanced stage and poor treatment completion contributed

30 cinoma (CCRCC) is an incurable malignancy in advanced stages and needs newer therapeutic targets.

31 or B3GALT5 was significantly associated with advanced stages and poor outcome.

32 indicate that LGR5 expression was reduced in advanced stages and positively correlated with markers o

33 In a patient-derived xenograft model of advanced-stage and platinum-resistant ovarian cancer, an

34 ative CA interface libraries have reached an advanced stage, and a number of automation workflows are

35 is a highly invasive cancer, diagnosed at an advanced stage, and refractory to surgical intervention

36 absence of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of

37 8 years or older) with previously untreated, advanced stage (Ann Arbor stage III or IV) follicular ly

38 Here we describe advanced stage appendiceal MAA presenting as inguinal ul

39 ial role for stratification of patients with advanced stage ARLD.

40 symptoms being more strongly associated with advanced stage at diagnosis than others, for most sympto

41 otic than pigmented melanoma because of more advanced stage at diagnosis.

42 th early-stage favorable than unfavorable or advanced stage at first diagnosis (15-year cumulative in

43 In a prospective study in patients with advanced-stage B-cell lymphoma, we investigated the prog

44 However, prostate cancer cells in advanced stages become resistant to inhibitory effects o

45 e 1 trial in all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab e

46 his Article, all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab e

47 malignancy is not uncommon in patients with advanced stage cancer.

48 r extrahepatic cancer are considered to have advanced-stage cancer and could benefit from treatment w

49 w that in the 2.7% and 1.8% of patients with advanced-stage cancer and germline pathogenic or somatic

50 Patients with advanced-stage cancer are receiving increasingly aggress

51 to overall cancer mortality in patients with advanced-stage cancer because prognosis remains poor des

52 clinical results in a significant number of advanced-stage cancer patients.

53 However, in advanced stages, cancer cells and infiltrating stromal c

54 wever, most previous studies have focused on advanced stage cancers, and few have evaluated ctDNA det

55 Many effective drugs for metastatic and/or advanced-stage cancers have been developed over the past

56 gly low at around 15-30% among patients with advanced-stage cancers other than melanoma.

57 precursor to HGSC and identifiable in 50% of advanced stage cases.

58 g in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease.

59 edullary thyroid carcinoma, as well as other advanced-stage CCK2R-expressing malignancies.

60 medications/drugs (EAR, 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7

61 Individuals age 60-74 years with advanced-stage cHL experienced a disproportionate excess

62 acy and safety profiles for newly diagnosed, advanced-stage cHL.

63 n is one of the treatments for patients with advanced stage chronic liver disease and for selected pa

64 Likewise, in the advanced-stage cohort, 7% of samples with a "localized-s

65 eous profiling of 140 tissue regions from 35 advanced-stage colorectal cancer (CRC) patients with 56

66 lan fibres, whereas septal elastosis at more advanced stages contained mainly mature elastic fibres.

67 Differences in attachment rate at this advanced stage correlate with local plasmonic field enha

68 as predictors of 5-year OS in patients with advanced-stage CRC.Keywords: Abdomen/GI, CT, Comparative

69 ells and disease activity in 8 patients with advanced-stage CTCL.

70 ted with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in

71 nts 18 years of age or older with untreated, advanced-stage (defined as III to IV and IIB with unfavo

72 with follicular lymphoma; P = .047) and with advanced stage disease (15 of 18 patients).

73 ating let-7b miRNA were associated with more advanced stage disease (i.e., III-IV vs. I-II) in DLBCL

74 investigate optimal treatment strategies for advanced stage disease in areas of high prevalence and l

75 t targeting this pathway may be effective in advanced stage disease.

76 C) is terminal in most patients with locally advanced stage disease.

77 might be simply expediting the detection of advanced stage disease.

78 In patients with advanced-stage disease (15 pregnant patients and 69 non-

79 Patients had advanced-stage disease (23 of 24 with stage IIB to IV MF

80 , 31; 4-6 months, 31; and 7-9 months, 43) or advanced-stage disease (cases per 1000 8-30 days, 8; 2 m

81 Risk of any colorectal cancer and advanced-stage disease (defined as stage III and IV canc

82 1.05-2.08]; 49 cases per 1000 patients) and advanced-stage disease (OR, 1.97 [95% CI, 1.14-3.42]; 19

83 1.89-2.68]; 76 cases per 1000 patients) and advanced-stage disease (OR, 3.22 [95% CI, 2.44-4.25]; 31

84 her likelihood of solid subtype ( P < .001), advanced-stage disease at diagnosis ( P = .02), higher r

85 sociation with risk of colorectal cancer and advanced-stage disease at diagnosis.

86 a higher risk of colorectal cancer and more advanced-stage disease at the time of diagnosis.

87 h better overall survival (OS) than that for advanced-stage disease but with continuous relapse regar

88 es of any colorectal cancer and 601 cases of advanced-stage disease diagnosed.

89 n colorectal tumors and its association with advanced-stage disease in patients.

90 Advanced-stage disease is common with uncharacteristic l

91 Curative therapy for cancer patients with advanced-stage disease remains elusive.

92 biologic agents available, the treatment of advanced-stage disease still represents an unmet medical

93 o clinical decision-making for patients with advanced-stage disease will soon become a reality.

94 Greater reductions in advanced-stage disease yielded a greater screening effec

95 term tumour control even in individuals with advanced-stage disease.

96 the success of future targeted therapies in advanced-stage disease.

97 %), the median age was 32 years, and 68% had advanced-stage disease.

98 ells, which are unlikely to be the origin of advanced-stage disease.

99 evelopment, and at distant sites, leading to advanced stage diseases.

100 e LNH073B trial (NCT00498043), patients with advanced-stage DLCBL and (18)F-FDG PET/CT images availab

101 These BE patients are at risk of developing advanced-stage EAC.

102 curring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.

103 o-occurring oncogenic events present in most advanced-stage EGFR-mutant lung cancers.

104 ncluded those with histologically confirmed, advanced-stage, EGFR-mutant NSCLC.

105 y downregulated in poorly differentiated and advanced-stage endometrial carcinoma compared with level

106 in a large national population of women with advanced-stage EOC.

107 (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC).

108 ed with NACT in otherwise healthy women with advanced-stage epithelial ovarian cancer aged 70 years o

109 hed strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer.

110 Advanced-stage epithelial ovarian cancers are amongst th

111 pokinetic nondilated phenotype, which in the advanced stages evolves into fibrosis without detectable

112 ignatures discriminating localized-stage and advanced-stage FL (area under the curve, 0.98) by penali

113 of localized-stage FL, patient cohorts with advanced-stage FL or localized-stage FL, uniformly treat

114 was performed in 110 localized-stage and 556 advanced-stage FL patients.

115 in two independent cohorts of patients with advanced-stage FL requiring systemic treatment (n = 138,

116 gical difference between localized-stage and advanced-stage FL that might contribute to the superior

117 population-based cohort of 296 patients with advanced-stage FL treated with frontline BR and maintena

118 firms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy.

119 ure could not be identified in patients with advanced-stage FL, consistent with results from global t

120 and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known

121 tenance as initial therapy for patients with advanced-stage follicular lymphoma (FL).

122 might represent a new therapeutic option for advanced-stage follicular lymphoma.

123 isone (CVP) in patients with newly diagnosed advanced-stage follicular lymphoma.

124 18)F-FDG avidity in the index malignancy, an advanced stage for that malignancy, and a clinician deci

125 metabolic activity was associated with more advanced stage, greater nutritional risk, the systemic i

126 nts either approved or awaiting approval for advanced stage HCC.

127 Advanced-stage HCC (BCLC B/C) showed higher frequencies

128 serve as a safe and effective treatment for advanced-stage HCC patients with tumor PVT.

129 the therapeutic situation for patients with advanced-stage HCC.

130 PDX models functionalize early and advanced stage HCCs and revealed unique biological featu

131 , early-stage unfavourable (HD14 trial), and advanced-stage (HD15 trial) Hodgkin's lymphoma.

132 Therapeutic options for patients with advanced-stage hepatocellular carcinoma (HCC) are very l

133 e report survival outcomes for patients with advanced-stage hepatocellular carcinoma (HCC) with porta

134 eighty newly diagnosed early unfavorable and advanced-stage HL patients, all scanned at baseline and

135 us and less toxic therapeutic approaches for advanced-stage HL patients.

136 Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excell

137 Patients with advanced-stage Hodgkin lymphoma for whom treatment was a

138 y during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a

139 ge favourable, early-stage unfavourable, and advanced-stage Hodgkin's lymphoma from the HD13, HD14, a

140 Lower survival of Appalachian males with advanced-stage HPV-associated oropharyngeal cancers sugg

141 .05-1.22), whereas no increase was found for advanced stages (HR = 0.98, 95% CI, 0.92-1.05).

142 25 Gy) for early stage (IA, IB, and IIA) and advanced stage (IIB-IV) with bulky disease.

143 Advanced-stage (IIB-IVB) HL patients, enrolled in the HD

144 ized as localized (stages I and II), locally advanced (stages III and IVB), or metastatic (stage IVC)

145 centage of fibrosis was larger and at a more advanced stage in group 1 versus group 2 and, within gro

146 0 degrees C, thus suggesting a release at an advanced stage in the reprocessing of nuclear fuel.

147 f TF has in clinical studies correlated with advanced stage, increased microvessel density, metastasi

148 (abscopal) cancer remission in patients with advanced stage iNHL in an ongoing trial ( NCT01976585 ).

149 In advanced-stage KS, chemotherapy with pegylated liposomal

150 fective treatment approach for patients with advanced-stage leukaemia.

151 urvival for salvage therapy of patients with advanced-stage lung adenocarcinoma.

152 improved survival outcomes for patients with advanced-stage lung cancer; however, this disease remain

153 ents and Methods We treated 22 patients with advanced-stage lymphoma in a clinical trial of CAR-19 T

154 y low-dose chemotherapy induced remission of advanced-stage lymphoma, and high serum IL-15 levels wer

155 ave revolutionized the treatment of multiple advanced-stage malignancies.

156 cardial disease; (2) the patient had a known advanced-stage malignancy; (3) the patient already have

157 filing the proteome of clinical samples from advanced stage melanoma patients undergoing either tumor

158 individuals presented with thick (>4 mm) or advanced-stage melanoma at diagnosis.

159 remains one of the deadliest malignancies as advanced stage metastatic disease is mostly untreatable,

160 (225)Ac-PSMA-617 alpha-radiation therapy in advanced-stage, metastatic castration-resistant prostate

161 macrophages in the tumor microenvironment of advanced stage MF by upregulating the expression of gene

162 don't survive 5 years, whereas patients with advanced-stage MF and Sezary syndrome have a 5-year surv

163 tages, n = 251; intermediate stages, n = 76; advanced stages, n = 144) who had received stage-adapted

164 Advanced stage NB is metastatic, which is a principal ca

165 re referred to surgery, and three cases with advanced stage neoplasia were also treated with chemothe

166 ite multi-modality treatments, prognosis for advanced stage neuroblastoma (NB) remains challenging wi

167 we analyzed longitudinal blood samples from advanced stage non-small cell lung cancer (NSCLC) patien

168 study with (18)F-BMS-986192 in patients with advanced-stage non-small cell lung cancer eligible for n

169 -3'-(18)F-fluorothymidine ((18)F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) pat

170 The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began

171 on-making in the management of patients with advanced-stage non-small-cell lung cancer (NSCLC) in lig

172 when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC.

173 for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplasti

174 sion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in

175 o inform value-based treatment decisions for advanced-stage NSCLC.

176 ctive genotyping in nearly all patients with advanced-stage NSCLC.

177 ersal primary chemoresistance; patients with advanced stage OCCC thus lack effective therapies and fa

178 ic conditions are all associated with a more advanced stage of cancer at diagnosis.

179 Benefits increased with advanced stage of cervical cancer and more efficient sca

180 Despite the advanced stage of diamond thin-film technology, with app

181 gency pathways that are associated with more advanced stage of disease at diagnosis.

182 outcomes if the targeted symptoms represent advanced stage of disease.

183 anisms underlie reduced MEE at the early and advanced stage of hypertrophic cardiomyopathy.

184 ovarian cancer patients are diagnosed at an advanced stage of metastatic disease.

185 age of NSCLC, but promote cell growth in the advanced stage of NSCLC.

186 n of Dmp1 and Dspp, respectively, during the advanced stage of odontoblast differentiation.

187 Critical limb ischemia (CLI) is the most advanced stage of peripheral artery disease, associated

188 lped to elucidate the general picture of the advanced stage of plant cell specialization and to revea

189 those that hold promise or are already at an advanced stage of testing (OsPSTOL1, AVP1, PHO1 and OsPH

190 unclear if laminin-111 protein therapy at an advanced stage of the disease can have beneficial outcom

191 f incurable disease status, knowledge of the advanced stage of the disease, and expectation to live m

192 with Retinitis Pigmentosa (RP) show, in the advanced stage of the disease, severely restricted perip

193 nic drugs, but geographic atrophy (GA) is an advanced stage of the more prevalent "dry" form of AMD f

194 proteolytic degradation of Abeta plaques in advanced stages of AD.

195 ls of complement, only uEVs of patients with advanced stages of ADPKD had increased levels of villin-

196 exaenoic acid (DHA) and the intermediate and advanced stages of age-related macular degeneration (AMD

197 ium of human eyes, particularly in eyes with advanced stages of age-related macular degeneration.

198 ith early (n = 9), intermediate (n = 5), and advanced stages of AMD (geographic atrophy, n = 5; neova

199 While reactive microgliosis is a hallmark of advanced stages of amyotrophic lateral sclerosis (ALS),

200 Intraleaflet hematomas are associated with advanced stages of aortic valve calcification and suspec

201 tween circulating PCSK9 and early as well as advanced stages of atherosclerosis in psoriasis.

202 on and myeloid cell recruitment at early and advanced stages of atherosclerosis.

203 This isoform is highly expressed in advanced stages of breast and cervical tumors.

204 ge proliferation is a significant feature of advanced stages of cancer.

205 endent prognostic indicator in patients with advanced stages of chronic lymphocytic leukaemia (CLL).

206 ed conditional approval and many more are at advanced stages of clinical development.

207 roved for therapeutic intervention or are in advanced stages of clinical development.

208 ious manifestations that are observed in the advanced stages of coronavirus disease 2019 (COVID-19) b

209 the SOCS1 peptidomimetic at either early or advanced stages of diabetes ameliorated STAT activity an

210 and volume are significantly reduced in more advanced stages of diabetic retinopathy.

211 ven percent of eyes in decade 1 demonstrated advanced stages of disease (stage 3B or worse) compared

212 have been documented in patients treated at advanced stages of disease, including improvement in liv

213 lgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after ch

214 proved survival, particularly in patients at advanced stages of disease.

215 y elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between

216 pidermal neuronal loss is more pronounced in advanced stages of DR, indicating a positive severity co

217 and in the eye with the development of more advanced stages of DR.

218 es were more profound in early compared with advanced stages of fibrosis (P < 0.05 for both).

219 At advanced stages of FSGS, fawn-hooded hypertensive rat ki

220 s, three of which became pregnant and are in advanced stages of gestation.

221 tential of Nmnat-mediated neuroprotection at advanced stages of HD.

222 g on episodic memory and motor function with advanced stages of HIV infection suggests that these two

223 c transport is compromised in both early and advanced stages of hypertension.

224 Behavioral fever manifested only at advanced stages of infection.

225 Older age and advanced stages of keratoconus were predictors of type 2

226 anhydroglucitol (1,5-AG) are associated with advanced stages of kidney disease independent of kidney

227 ted endogenous antioxidants in predominantly advanced stages of kidney disease.

228 By contrast, in advanced stages of Kras-driven murine PDAC, loss of p53

229 Advanced stages of liver cirrhosis lead to a dramaticall

230 important, especially for patients with more advanced stages of lung disease.

231 (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases i

232 acle" outcomes seen in a few patients at the advanced stages of melanoma or lung cancer, the immune c

233 w being used more commonly for patients with advanced stages of melanoma, can exacerbate autoimmune d

234 athogenic bacteria is highly associated with advanced stages of MRONJ lesions; however, the exact rol

235 Advanced stages of neuroblastoma, the most common extrac

236 at higher risk of TKR, particularly at less advanced stages of OA, such that appropriate treatments

237 ocyte levels were significantly increased in advanced stages of PAOD, while classical and non-classic

238 The use of HA in advanced stages of peri-implantitis resulted in a decrea

239 sults show that the retinal transcriptome at advanced stages of RP is very similar to that of other r

240 ne, many questions are yet to be answered in advanced stages of the cancer: what subset of patients m

241 ement in SCA1 mice even when administered at advanced stages of the disease.

242 n increase in proinflammatory MC function in advanced stages of the disease.

243 r are subtle and become apparent only during advanced stages of the disease.

244 the disease progresses, often dominating the advanced stages of the disease.

245 Markers of the early and advanced stages of the Maillard reaction were also follo

246 ate well with reactive lysine content if the advanced stages of the reaction had not been reached.

247 ogs, rcd1 and xlpra2, at clinically relevant advanced stages of the two diseases.

248 a acts as a tumor suppressor, whereas in the advanced stages of these cancers, increased TGF-beta exp

249 ; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly

250 ecause NAFLD is a heterogeneous disease, the advanced stages of which seem to be strongly affected by

251 ocalised disease; however, for patients with advanced stage or unresectable disease, locoregional and

252 orm in HCC patients, particularly those with advanced staging or larger nodule size.

253 For patients with advanced-stage or metastatic disease, comprehensive geno

254 ombotic state among individuals afflicted by advanced-stage OSCC.

255 e surgery (PCS) by identifying patients with advanced-stage ovarian cancer in whom > 1 cm of residual

256 Patients with suspected advanced-stage ovarian cancer who qualified for PCS were

257 alignant ascites or tissues of patients with advanced-stage ovarian cancer, pretreatment with Mdivi-1

258 tile laparotomies in patients with suspected advanced-stage ovarian cancer.

259 e rate and thyroid cancer mortality rate for advanced-stage papillary thyroid cancer.

260 Patients with disease diagnosed at advanced stages, particularly when heart involvement is

261 We compared advanced stage patients with HCC (American Joint Committ

262 diagnosis (and were otherwise untreated) to advanced stage patients with HCC who received no therapy

263 nitial therapeutic response, the majority of advanced-stage patients relapse and succumb to chemoresi

264 For advanced-stage patients who were event free at 2 years,

265 For advanced-stage patients, a treatment activity of 100 kBq

266 It can achieve unprecedented responses in advanced-stage patients, including complete cures and lo

267 helial-to-mesenchymal transition features in advanced-stage patients, suggesting greater potential fo

268 diagnosis of malignancy and the detection in advanced stages, patients should be referred for treatme

269 dence interval [CI]: 1.01, 3.5; P = .04) and advanced stage PDAC (10.8 months vs 18.0 months; HR, 2.1

270 l lung cancer (NSCLC) cases are diagnosed at advanced stages, primarily because earlier stages of the

271 While the majority of advanced-stage prostate cancer patients will initially r

272 Nevertheless, the majority of advanced-stage prostate cancer patients, including those

273 Advanced-stage prostate cancer usually metastasizes to b

274 no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death due to prostate

275 -617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer.

276 -year cumulative risk of cancer after LT for advanced-stage PSC was 18.7%, with posttransplant lympho

277 or-initiating cells (TIC) is vital to combat advanced-stage recurrent cancers.

278 ), unilateral disease (5.00, 3.45-7.14), and advanced stage (regional 4.71, 2.51-8.84; distant 3.15,

279 e early phases, whereas in patients with the advanced stages, several therapeutic strategies can be u

280 , this region appears crescent-shaped, while advanced stages show a ring-like pattern.

281 Of note, 3% of samples harboring an "advanced-stage signature" in the localized-stage cohort

282 argeted therapy are rare in individuals with advanced-stage solid cancers.

283 age thyroid cancer, whereas the incidence of advanced-stage thyroid cancer has increased marginally.

284 tion of many diseases currently diagnosed at advanced stages today.

285 Advanced stage tumor diagnosis is likely attributable to

286 ARs, namely PAR-2, which is overexpressed in advanced stage tumors and is activated by trypsin-like s

287 multi-center integrated genomic analysis of advanced stage tumors with and without STIC lesions and

288 opean cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate cancer.

289 5OHD concentrations were lower in women with advanced-stage tumors, and the lowest in premenopausal w

290 ve increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer.

291 eral ocular involvement at presentation, and advanced stage were significantly correlated with shorte

292 ith the majority of patients diagnosed at an advanced stage where curative therapeutic options are la

293 han 5 months, with most patients being in an advanced stage wherein the survival rate is very low.

294 arcinoma (PDAC) is typically diagnosed at an advanced stage, which limits surgical options and porten

295 y and mortality owing to diagnosis at a more advanced stage, which suggests that nonwhite organ trans

296 inical data and CT, or with equivocal CT for advanced stage, who were considered for curative-intent

297 th NAFLD, isolated steatosis can progress to advanced stages with non-alcoholic steatohepatitis (NASH

298 e largest excess mortality and represents an advanced stage within the AR clinical spectrum.

299 s the disease only becomes symptomatic at an advanced stage, worldwide organised screening programmes

300 CRC has high mortality when detected at advanced stages, yet it is also highly preventable.